Similar to the cell culture experiments, we showed that lung cancer cells that were tolerant to osimertinib expressed high levels of PAI-1 (Figure 5B,C), indicating that PAI-1 inhibitors could suppress PAI-1-related EMT and inhibit the regrowth of osimertinib-treated tumors. Here, SERPINE1 is linked to lung carcinoma.